Blog

Companion Diagnostics (CDx)—A Central Laboratory Perspective Companion Diagnostics Alan Wookey Companion Diagnostics (CDx)—A Central Laboratory Perspective
In the June issue of Inside Precision Medicine, Alan Wookey, Vice President Companion Diagnostics and Q2 Solutions’ scientific advisor, explores the evolution of companion diagnostics (CDx) since the...
Biospecimen and consent management Central Laboratories Technology Brian O’Dwyer Biospecimen and consent management
Would you place your full trust in a healthcare provider that kept your medical records in spreadsheets or paper files? Not likely. But every day, one of our most valued business assets – biospecimen...
Immunotherapy and PD-L1: A primer Biomarkers Companion Diagnostics Radha Krishnan Immunotherapy and PD-L1: A primer
Advances in precision medicine have led to a shift in paradigm for oncology research, from targeted therapies that rely largely on tyrosine kinase inhibitors (TKIs) to personalized therapy that can...
Immunotherapy takes center stage on World Cancer Day Clinical Trials Central Laboratories Kathleen Gray Immunotherapy takes center stage on World Cancer Day
Author: Kathleen Gray, PhDThis is an exciting time to be working in the field of cancer research. Throughout the last few years, amazing strides have been made toward the ultimate goal: to turn...
Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options by Victor Weigman Genomics Precision Medicine Victor Weigman, Ph.D. Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options by Victor Weigman
Authors: Victor Weigman, Ph.D. & Patrice Hugo, Ph.D.With advancements in clinical informatics and genomics, there has been a paradigm shift from “one drug fits all” toward precision medicine – taking...